Marex Group

Recent news

• Rating change
  Barclays Maintains Marex Group(MRX.US) With Buy Rating, Raises Target Price to $60
  Market Newswire · 2026/5/11
• Company notice
  Shanghai Mecan Pharma Co., Ltd. voluntarily discloses an announcement regarding the approval granted to MRX-5 in the United States to commence clinical trials.
  SZSI · 2026/1/29
• Barclays Maintains Marex Group(MRX.US) With Buy Rating, Raises Target Price to $86
  Market Newswire · 2026/8/13
• UBS Maintains Marex Group(MRX.US) With Buy Rating, Raises Target Price to $90
  Market Newswire · 2026/8/13
• Company notice
  Mengke Pharmaceutical: Shanghai Mengke Pharmaceutical Co., Ltd. Voluntarily Discloses an Announcement Regarding the Approval Granted to MRX-5 in the United States to Conduct Clinical Trials
  SZSI · 2026/1/29
• Rating change
  Barclays Maintains Marex Group(MRX.US) With Buy Rating, Maintains Target Price $76
  Market Newswire · 2026/8/10
• Company notice
  Shanghai Mengke Pharmaceutical Co., Ltd. voluntarily disclosed the announcement on the successful completion of the MRX-4 phase III clinical trial for injectable use in China
  SZSI · 2024/11/28
• Rating change
  TD Cowen Maintains Marex Group(MRX.US) With Buy Rating, Raises Target Price to $67
  Market Newswire · 2026/5/7
• Company notice
  Announcement on voluntary disclosure of MRX-5 Australian Phase I clinical trial results by Shanghai Mengke Pharmaceutical Co., Ltd.
  SZSI · 2024/10/25
• Piper Sandler Maintains Marex Group(MRX.US) With Buy Rating, Raises Target Price to $80
  Market Newswire · 2026/10/2
• Form 144 | Marex Group(MRX.US) Officer Proposes to Sell 5.34 Million in Common Stocks
  Market Newswire · 2026/9/15
• Company notice
  Shanghai Mengke Pharmaceutical Co., Ltd. voluntarily disclosed the announcement that the MRX-5 clinical trial application was approved
  SZSI · 2025/1/4
• Rating change
  Barclays Maintains Marex Group(MRX.US) With Buy Rating, Raises Target Price to $76
  Market Newswire · 2026/7/9
• Rating change
  Barclays Maintains Marex Group(MRX.US) With Buy Rating, Maintains Target Price $55
  Market Newswire · 2026/5/7
• Rating change
  Piper Sandler Maintains Marex Group(MRX.US) With Buy Rating, Raises Target Price to $75
  Market Newswire · 2026/7/15
• Rating change
  TD Cowen Maintains Marex Group(MRX.US) With Buy Rating, Raises Target Price to $75
  Market Newswire · 2026/6/8
• Rating change
  KBW Maintains Marex Group(MRX.US) With Buy Rating, Raises Target Price to $90
  Market Newswire · 2026/8/13
• Rating change
  KBW Maintains Marex Group(MRX.US) With Buy Rating, Raises Target Price to $80
  Market Newswire · 2026/7/10
• Rating change
  Goldman Sachs Maintains Marex Group(MRX.US) With Buy Rating, Raises Target Price to $62
  Market Newswire · 2026/5/8
• KBW Maintains Marex Group(MRX.US) With Buy Rating, Maintains Target Price $90
  Market Newswire · 2026/8/13

Headlines are aggregated automatically and are not independently verified or edited by our team.